Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up

doi:10.3748/wjg.v24.i3.438

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10184)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

804

WORD

415

HTML

5403

Figures (1-3)

511

Tables (1-1)

488

Sum=7621

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1116

Download

1444

Sum=2560

Jan 21, 2018 (publication date) through Dec 1, 2025

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Gastroenterol. Jan 21, 2018; 24(3): 438-444
Published online Jan 21, 2018. doi: 10.3748/wjg.v24.i3.438

Table 1 Measurements of hepatic hemodynamic parameters

Time		Flow portal vein (L/min)		Flow umbi-lical vein (L/min)	HVPG (mmHg)	Blood pressure (mmHg)	Heart rate (beats/min)
		Duplex	MRI	MRI
Start	02/2009	0.97	0.85	0.53	10.5	130/87	69
1 h post Vardenafil 10 mg	02/2009	1.24	0.99	0.56	9.0 (-14%)	121/75	61
4 mo Tadalafil 5 mg/d	06/2009		1.21	0.56	10.5	127/77	64
Without PDE-5-I	10/2009				12
1h post Tadalafil 5 mg	10/2009	1.28	0.99	0.53	10.0 (-15%)	110/70	84
11 mo Tadalafil 5 mg/d	03/2010	1.32	1.33		10.5	120/80	70
20 mo Tadalafil 5 mg/d	10/2010	1.34				115/75	77
26 mo Tadalafil 5 mg/d	04/2011	1.26	1,34			125/80	72
32 mo Tadalafil 5 mg/d	10/2011	1.25				117/70	66
46 mo Tadalafil 5 mg/d	12/2012	1.20				131/85	70
53 mo Tadalafil 5 mg/d	07/2013	1.20				110/70	68
60 mo Tadalafil 5 mg/d	02/2014	1.20				115/75	78
70 mo Tadalafil 5 mg/d	12/2014	1.20				110/70	70
81 mo Tadalafil 5 mg/d	11/2015	1.40				135/85	65
84 mo Tadalafil 5 mg/d	12/2016	1.06¹				135/75	85
93 mo Tadalafil 5 mg/d	09/2017	1.29				110/70	80

¹The duplexsonography at month 84 was done with a different device.

Full Size Table

Citation: Deibert P, Lazaro A, Stankovic Z, Schaffner D, Rössle M, Kreisel W. Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. World J Gastroenterol 2018; 24(3): 438-444
URL: https://www.wjgnet.com/1007-9327/full/v24/i3/438.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i3.438